Clinical Trial Update: VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)

View source ↗

Summary

A real-life multicenter study (DOPER) examining Vedolizumab persistence in inflammatory bowel disease after switching from intravenous to subcutaneous administr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Diseases

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Conditions: Inflammatory Bowel Diseases | Status: ACTIVE_NOT_RECRUITING